A Phase 4 interventional study of Acetyl cysteine and Normal (0.9%) saline in Ventilation Acquired Pneumonia, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-07-10.
Sponsored by Cairo University · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Pneumonia by Cairo University — 4 open to participants now, 4 under way, none of them phase 3. Pneumonia · Cairo University.
Among the 13 studies in Pneumonia by Cairo University, this one is the 3rd largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2026, is the only one in phase 4, and was the 13th registered.
1,569 studies on the registry are indexed under Pneumonia; 267 are open to participants now.
Browse Pneumonia studies →4 of the 13 studies in Pneumonia by Cairo University are open now, in 1 country. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 49–65
Cairo University · Sites in Egypt
Ages 40–50
Cairo University
Ages 4–7
By country, each count listing its studies:
Of the 159 Pneumonia studies recruiting now, 84 (53%) set no upper age limit and 48 (30%) stop at 75 or younger; 40 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is below the median of 128 across 978 interventional studies indexed under Pneumonia.
Median enrollment 60 across the 11 interventional studies, 76 across the 2 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Cairo University is the lead sponsor of 4,967 studies on the registry; 1,474 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Pneumonia by Cairo University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Background Mechanical ventilation is an essential medical intervention in the context of critical illness. However, the intervention is associated with a risk of significant, potentially preventable complications. Among these are ventilator-associated pneumonia, sepsis, acute respiratory distress syndrome, atelectasis, and pulmonary edema.
Ventilator-associated complications commonly increase morbidity and mortality. They may also prolong the duration of mechanical ventilation and the length of stay in the hospital or the intensive care unit, with increased health care costs; so safe, effective therapeutic and preventative strategies are essential to attenuate poor outcomes from ventilator-associated events.
Secretion retention and ineffective cough play a significant role in failed extubation and weaning from ventilator; the presence of the artificial airway, poor humidification of inspired gases, and immobility are the major causes of pulmonary secretion retention in this population. Accumulated secretion in the airways, if extensive, starts a self-sustaining cycle of ventilation/perfusion mismatch, gas-exchange impairment, increased work of breathing.
For decades N-acetyl-L-cysteine (NAC) has been used for its mucolytic properties orally in different respiratory diseases like chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and cystic fibrosis (CF); but its effects are not known if given by nebulization through endotracheal tube (ETT), studies to date have provided inconclusive results. Despite this uncertainty, mucoactive agents are still used in adult ICUs.
NAC is usually administered orally, with several formulations and dosage forms available for both short- and long-term treatment of respiratory diseases. The inhalation route might also be considered a practical option, with recent interest, as the therapeutic drug acts directly on the bronchial mucosa, promotes continuous local retention of the drug, prolongs anti-inflammatory effects, and avoids the liver first-pass effect, which can help quickly improve airway inflammation.
Contrary to other mucoactive drugs, NAC has been found to exhibit antioxidant, anti-inflammatory, antibacterial, and antibiofilm activities.
In the respiratory infection field, the available data indicate that NAC was associated with inhibition of oxidative stress and reduced the inflammatory factors in community acquired pneumonia, antibiofilm activity specially in pseudomonas aeruginosa infection in pre-clinical and clinical reports and has good antibacterial properties and suggested to interfere with biofilm formation and disruption.
NAC has shown improvement in the respiratory index (PaO₂/FiO₂), with lower rates of mechanical ventilation in COVID-19. When studied in mechanically ventilated patients with acute respiratory distress syndrome (ARDS), which is associated with oxidative stress, increased levels of glutathione, and inflammation, NAC demonstrated improvements in positive end-expiratory pressure (PEEP) and PaO₂/FiO₂.
N-Acetylcysteine contributed to delaying ventilator-associated pneumonia (VAP) in mechanically ventilated patients when administered orally as a preventive medication. It was also effective in attenuating the decline in forced vital capacity (FVC) in mild to moderate idiopathic pulmonary fibrosis (IPF), and it showed a lower rate of postoperative pulmonary complications when given pre-operatively in orthotopic liver transplantation.
Since NAC is relatively low-cost, readily available, and has a favorable side effect profile, it is important to properly assess the clinical benefits of nebulized NAC as an adjunct to standard medical treatments in mechanically ventilated patients.
Aim of the study
This study will assess the role of preventive N-acetylcysteine inhalation on incidence and time to develop VAP in critically ill mechanically ventilated patients.
Objectives
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Presence of a condition or abnormality that would compromise the quality of the data.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
40 adult patients receiving 3ml normal saline 0.9% inhalation every 12hrs using Aerogen solo nebulizers
Drug: Normal (0.9%) saline
40 adults patients receiving 3ml acetylcysteine inhalation every 12hrs using Aerogen solo nebulizers.
Drug: Acetyl cysteine
40 adult mechanically ventilated patients will receive 3ml acetyl cysteine 10% nebulised every 12 hours .Nebulization will be performed using a vibrating mesh nebulizer ( Aerogen solo) placed in the inspiratory limb of the ventilator tubing, behind the Y-piece, and continued until the nebulizer deposit becomes dry.
40 adult mechanically ventilated patients will receive 3ml normal saline nebulised every 12 hours. Nebulization will be performed using a vibrating mesh nebulizer (Aerogen solo) placed in the inspiratory limb of the ventilator tubing, behind the Y-piece, and continued until the nebulizer deposit becomes dry
The primary endpoint of interest is incidence and time to develop ventilator associated pneumonia.
1. Incidence of VAP will be expressed as percentage of patients who developed VAP. 2. Time to develop VAP is expressed in days
Time frame: participant will be followed up for 10 days post mechanical ventilation or till extubation (whichever occurs first).
1) Infection parameters (TLC,Temperature °C) 2)Change in P/F ratio 3) Duration of mechanical ventilation expressed in days 4) Day 3 ETT aspirate culture positivity 5) Number of endotracheal tube exchange and suctioning episodes per ventilator day.
1. Change in infection parameter TLC (×10⁹/L), CRP (mg/L), body temperature (°C) from base line to day 10 post intubation or till extubation 2. Change in (P/F ratio measured in mmHg) from baseline to day 10 post intubation or till extubation 3. Positive vs negative ETA culture 4. Incidence and time to develop Ventilator associated tracheobronchitis.
Time frame: participant will be followed up for 10 days post mechanical ventilation or till extubation (whichever occurs first)
Plan to share: Yes
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Mar 2028, 24 months after the start.
Of 42 non-industry phase 4 interventional studies under Pneumonia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 43. This study's planned 24 months is below that.
Counting every sponsor, half of 49 studies reached it within 31 months; a quarter within 21 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acetylcysteine